The clinical correlation between AREG and COX‐1/COX‐2 expression in melanoma further supports targeting prostaglandin synthesis (e.g., COX inhibitors) as a strategy to disrupt this axis (Figure 5I). This evidence concerns the gene PTGS2 and melanoma.